Tillotts Pharma competitive analysis

Explore patent oppositions filed by Tillotts Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jan 29, 2026
Patent NumberTitleApplicantOpposition Date
Controlled-Release Granular Compositions Containing Mesalazine And Process For The Manufacture ThereofSOFARFeb 28, 2019
Mesalazine Tablet Having Improved DissolutionDISPHARNov 21, 2018
Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 5, 2018

Explore Tillotts Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jan 29, 2026
Patent NumberPublication DateTitleTotal Oppositions
Nov 23, 2022Preparation Of Solid Dosage Forms Comprising Antibodies By Solution/Suspension Layering1

Latest PTAB cases involving Tillotts Pharma

Discover the latest PTAB cases involving Tillotts Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Tillotts Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jan 29, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
TILLOTTS PHARMA31 - -
CHUGAI SEIYAKU KABUSHIKI KAISHA378 - 1
DISPHAR - 1 - -
HEIROTH1 - - -